Publikasi Scopus 2024 per tanggal 31 Mei 2024 (409 artikel)

Authors

Tenggara J.B.; Rachman A.; Prihartono J.; Rachmadi L.; Panigoro S.S.; Heriyanto D.S.; Sutandyo N.; Nasution I.R.; Rahadiati F.B.; Steven R.; Betsy R.; Juanputra S.; Sudoyo A.W.

Author_Full_Names

Tenggara, Jeffry Beta (26028154300); Rachman, Andhika (15056701600); Prihartono, Joedo (6602605635); Rachmadi, Lisnawati (55062422000); Panigoro, Sonar Soni (56790104300); Heriyanto, Didik Setyo (54420130300); Sutandyo, Noorwati (26028099200); Nasution, Intan Russianna (58856886500); Rahadiati, Familia Bella (57222312428); Steven, Ricci (58808727700); Betsy, Rachelle (58035832700); Juanputra, Samuel (58035300800); Sudoyo, Aru Wisaksono (6507478291)

Author S Id

26028154300; 15056701600; 6602605635; 55062422000; 56790104300; 54420130300; 26028099200; 58856886500; 57222312428; 58808727700; 58035832700; 58035300800; 6507478291

Title

The relationship between high ratios of CD4/FOXP3 and CD8/CD163 and the improved survivability of metastatic triple-negative breast cancer patients: a multicenter cohort study

Year

2024

Source Title

BMC Research Notes

Volume

Issue

Art No

Page Start

Page End

Page Count

Cited By

Link

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85183752630&doi=10.1186%2fs13104-024-06704-z&partnerID=40&md5=de027f325777bb9ecbe793095eb9ae40

Affiliations

Division of Hematology and Medical Oncology, Department of Internal Medicine, Dr. Cipto Mangunkusumo General Hospital–Faculty of Medicine Universitas Indonesia, Jl. Pangeran Diponegoro No. 71, RW.5, Kec. Senen, Central Jakarta, Jakarta, 10430, Indonesia; Division of Hematology and Medical Oncology, Department of Internal Medicine, MRCCC Siloam Hospital Jakarta, Jakarta, Indonesia; Department of Community Medicine, Dr. Cipto Mangunkusumo General Hospital–Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Anatomical Pathology, Dr. Cipto Mangunkusumo General Hospital–Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Surgical Oncology, Dr. Cipto Mangunkusumo General Hospital–Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Anatomical Pathology, Dr. Sardjito Hospital–Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; Division of Hematology and Medical Oncology, Department of Internal Medicine, Dharmais National Cancer Hospital, Jakarta, Indonesia; Division of Hematology and Medical Oncology, Gatot Soebroto Army Hospital Jakarta, Jakarta, Indonesia; Department of Anatomical Pathology, Gatot Soebroto Army Hospital Jakarta, Jakarta, Indonesia; Department of Internal Medicine, Dr. Cipto Mangunkusumo General Hospital–Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia

Authors With Affiliations

Tenggara J.B., Division of Hematology and Medical Oncology, Department of Internal Medicine, Dr. Cipto Mangunkusumo General Hospital–Faculty of Medicine Universitas Indonesia, Jl. Pangeran Diponegoro No. 71, RW.5, Kec. Senen, Central Jakarta, Jakarta, 10430, Indonesia, Division of Hematology and Medical Oncology, Department of Internal Medicine, MRCCC Siloam Hospital Jakarta, Jakarta, Indonesia; Rachman A., Division of Hematology and Medical Oncology, Department of Internal Medicine, Dr. Cipto Mangunkusumo General Hospital–Faculty of Medicine Universitas Indonesia, Jl. Pangeran Diponegoro No. 71, RW.5, Kec. Senen, Central Jakarta, Jakarta, 10430, Indonesia, Division of Hematology and Medical Oncology, Department of Internal Medicine, MRCCC Siloam Hospital Jakarta, Jakarta, Indonesia; Prihartono J., Department of Community Medicine, Dr. Cipto Mangunkusumo General Hospital–Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Rachmadi L., Department of Anatomical Pathology, Dr. Cipto Mangunkusumo General Hospital–Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Panigoro S.S., Department of Surgical Oncology, Dr. Cipto Mangunkusumo General Hospital–Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Heriyanto D.S., Department of Anatomical Pathology, Dr. Sardjito Hospital–Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia; Sutandyo N., Division of Hematology and Medical Oncology, Department of Internal Medicine, Dharmais National Cancer Hospital, Jakarta, Indonesia; Nasution I.R., Division of Hematology and Medical Oncology, Gatot Soebroto Army Hospital Jakarta, Jakarta, Indonesia; Rahadiati F.B., Department of Anatomical Pathology, Gatot Soebroto Army Hospital Jakarta, Jakarta, Indonesia; Steven R., Division of Hematology and Medical Oncology, Department of Internal Medicine, Dr. Cipto Mangunkusumo General Hospital–Faculty of Medicine Universitas Indonesia, Jl. Pangeran Diponegoro No. 71, RW.5, Kec. Senen, Central Jakarta, Jakarta, 10430, Indonesia, Division of Hematology and Medical Oncology, Department of Internal Medicine, MRCCC Siloam Hospital Jakarta, Jakarta, Indonesia; Betsy R., Department of Internal Medicine, Dr. Cipto Mangunkusumo General Hospital–Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Juanputra S., Department of Internal Medicine, Dr. Cipto Mangunkusumo General Hospital–Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Sudoyo A.W., Division of Hematology and Medical Oncology, Department of Internal Medicine, Dr. Cipto Mangunkusumo General Hospital–Faculty of Medicine Universitas Indonesia, Jl. Pangeran Diponegoro No. 71, RW.5, Kec. Senen, Central Jakarta, Jakarta, 10430, Indonesia, Division of Hematology and Medical Oncology, Department of Internal Medicine, MRCCC Siloam Hospital Jakarta, Jakarta, Indonesia

Abstract

Background: Triple-negative breast cancer (TNBC) has been documented as the most aggressive subtype of breast cancer. This study aimed to analyze antitumor and protumor immune activities, and their ratios as significant prognostic biomarkers in metastatic TNBC (mTNBC). Methods: A multicenter cohort study was conducted among 103 de novo mTNBC patients. The expression of CD8 and CD163 was evaluated using immunohistochemistry staining, CD4 and FOXP3 using double-staining immunohistochemistry, and PD-L1 using immunohistochemistry and RT-PCR. Results: Multivariate analysis revealed that high CD4/FOXP3 (HR 1.857; 95% CI 1.049–3.288; p = 0.034) and the CD8/CD163 ratio (HR 2.089; 95% CI 1.174–3.717; p = 0.012) yield significantly improved 1 year overall survival (OS). Kaplan–Meier analysis showed that high levels of CD4 (p = 0.023), CD8 (p = 0.043), CD4/FOXP3 (p = 0.016), CD8/FOXP3 (p = 0.005), CD8/CD163 (p = 0.005) ratios were significantly associated with higher rate of 1 year OS. Furthermore, 1 year OS was directly correlated with antitumor CD4 (R = 0.233; p = 0.018) and CD8 (R = 0.219; p = 0.026) and was indirectly correlated with protumor CD163 and FOXP3 through CD4/FOXP3 (R = 0.282; p = 0.006), CD4/CD163 (R = 0.239; p = 0.015), CD8/FOXP3 (R = 0.260; p = 0.008), and CD8/CD163 (R = 0.258; p = 0.009). Conclusion: This is the first study to demonstrate that high levels of CD4/FOXP3 and CD8/CD163 significantly improved the 1 year OS in de novo mTNBC patients. Thus, we recommend the application of these markers as prognosis determination and individual treatment decision. © 2024, The Author(s).

Author Keywords

CD163; CD4; CD8; FOXP3; Metastatic; Survival; Triple-negative breast cancer

Index Keywords

B7-H1 Antigen; CD8-Positive T-Lymphocytes; Cohort Studies; Forkhead Transcription Factors; Humans; Lymphocytes, Tumor-Infiltrating; Neoadjuvant Therapy; Triple Negative Breast Neoplasms; forkhead transcription factor; FOXP3 protein, human; programmed death 1 ligand 1; CD8+ T lymphocyte; clinical trial; cohort analysis; genetics; human; metabolism; multicenter study; neoadjuvant therapy; pathology; triple negative breast cancer; tumor associated leukocyte

Funding Details

Department of Anatomical Pathology; Department of Internal Medicine, University of Utah; Department of Radiology, Weill Cornell Medical College

Funding Text

The authors gratefully acknowledged all staff of the medical record, the Department of Radiology, the Department of Hematology and Medical Oncology, the Department of Anatomical Pathology (Deny Suprihatin), and the Clinical Epidemiology Division, Department of Internal Medicine (Utami Susilowati).

Publisher

BioMed Central Ltd

Issn

17560500

Isbn

Pubmed Id

38308298

Document Type

Article

Sjr Best Quartile

Sjr

534

Sjr Rank

9718